SuppData from Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Year: 2023
Type: other
Abstract: Additional Methods: MTD determination; Biomarker analyzed Supplementary Table S1. Patient disposition by treatment group Supplementary Table S2. Treatment-related AEs reported in >10% of patients in arm A Supplementary Table S3. Treatment-related AEs reported in in {greater than or equal to}2 patients in arm B Supplementary Table S4. Treatment-related AEs reported in >20% of patients in arm C Supplementary Table S5 Median treatment duration and dose reductions/delays by treatment group Supplementary Table S6. Treatment discontinuations by treatment group Supplementary Table S7. Glasdegib pharmacokinetic parameters at the RP2D Supplementary Table S8. Best overall response in patients with AML by treatment arm Supplementary Table S9. Selected baseline characteristics including gene mutations and response to treatment Supplementary Figure S1. Potential associations of MMP-3 and SDF-1 with response in patients administered glasdegib plus cytarabine/daunorubicin
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361924270